Next Investors logo grey

Shares kick on open as BOD Australia releases double dose of good news


Published 18-MAY-2021 11:44 A.M.


3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Medicinal Cannabis, CBD and hemp healthcare products company, Bod Australia Limited (ASX: BDA) has provided a promising update on its new medicinal cannabis product launch, as well as highlighting recent MediCabilisTM prescription growth in the United Kingdom.

Such was the positive response to today’s news that the company’s shares traded approximately 9% higher shortly after the market opened.

BDA is launching a new cannabigerol (CBG) product, which will be sold under the MediCabilis brand as MediCabilisTM CBG 50 in the United Kingdom.

CBG is a non-intoxicating cannabinoid compound in the cannabis plant, which holds strong therapeutic potential for use in broad therapeutic applications.

Preliminary research indicates that CBG has unique pharmacological actions and has the potential to address alternative therapeutic areas to THC and CBD.

CBG has a different chemical structure to CBD and THC and will bind onto specific cell receptors for different therapeutic targets.

BDA is launching the product following R&D assessments, with the introduction being part of the management’s approach to developing specific cannabis cultivators and product formats for current and future new product development.

The market for CBG is in its early stages and is expected to grow significantly in the coming years.

29 - BDA.PNG

First mover advantage with CBG 50 offers competitive benefits

The launch of MediCabilisTM CBG 50 will provide BDA with a first-mover position that will provide competitive advantages going forward.

Initially, BDA will focus on launching the product in the UK through select doctors and healthcare physicians.

The introduction of MediCabilisTM CBG 50 is also expected to support incremental market growth across the region, as well as providing additional R&D and clinical research opportunities.

Discussing these developments, chief executive Jo Patterson said, “The launch of a new CBG product, under the widely recognised MediCabilisTM brand will provide the company with a number of opportunities to increase prescription sales and scale up R&D.

"CBG has been reported to be the ‘next CBD’ and has a growing market demand.

"Published scientific literature suggests that CBG has potential anti-inflammatory benefits, so the launch of MediCabilisTM CBG 50 in oil form will provide Bod with an important first-mover advantage in what will become a significant market.’’

Quarter-on-quarter MediCabilisTM prescription growth an impressive 90%

In another positive development, BDA has reported strong quarter-on-quarter MediCabilisTM prescription growth in the UK.

During the March quarter of fiscal 2021, the company filled a total of 59 MediCabilisTM units, marking a 90% increase on the previous quarter (Q2 FY2021 prescriptions: 31).

BDA expects that UK MediCabilisTM prescription volumes will continue an upward trajectory following the launch of the company’s new CBG product, Project Twenty21 scale-up and ongoing educational initiatives to promote the company’s products with approved prescribers in the UK market.

Discussing the group’s strategy in relation to growing market share, Patterson said, "The recent upward trajectory in MediCabilisTM prescriptions is also very pleasing and follows considerable hard work undertaken in collaboration with our distribution partners and approved prescribers in the UK.

"To further scale up UK medicinal cannabis sales, Bod is progressing educational initiatives, as well as working with large industry bodies to grow its market share.

"This is a similar approach to how the company has tackled the Australian market and we expect growth to continue over the remainder of the calendar year and beyond.”

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.